Diazepam kinetics in patients with renal insufficiency or hyperthyroidism

Area of Science:

• Pharmacology
• Nephrology
• Endocrinology

Background:

• Drug pharmacokinetics can be altered by disease states.
• Diazepam is a commonly used anxiolytic and sedative medication.
• Understanding how renal failure and hyperthyroidism affect diazepam is crucial for safe prescribing.

Purpose of the Study:

• To investigate the impact of end-stage renal failure and hyperthyroidism on diazepam pharmacokinetics.
• To compare diazepam's half-life, clearance, and distribution in patients with renal failure and hyperthyroidism versus healthy controls.

Main Methods:

• Single intravenous dose of diazepam administered to patients with end-stage renal failure, hyperthyroidism, and healthy controls.
• Serial blood sampling over 7 days to measure diazepam concentrations.
• Pharmacokinetic analysis of total and unbound diazepam, including half-life, clearance, and volume of distribution.

Main Results:

• Diazepam half-life was significantly reduced in renal failure patients (37 h) compared to controls (92 h).
• Unbound diazepam fraction increased in renal failure patients, leading to reduced volume of distribution for the unbound drug.
• Intrinsic clearance of unbound diazepam did not differ significantly between renal failure patients and controls.
• No significant differences in diazepam kinetic variables were observed in hyperthyroid patients compared to controls.

Conclusions:

• End-stage renal failure alters diazepam protein binding and distribution, but not the clearance of the active unbound drug.
• Thyrotoxicosis does not appear to influence diazepam pharmacokinetics.
• These findings suggest that while renal disease affects diazepam's disposition, the elimination of the active form remains largely unchanged.